| 9th Feb 2023 7:00 am |
RNS |
Full Year Trading Update |
| 23rd Jan 2023 11:15 am |
EQS |
Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital |
| 13th Jan 2023 10:30 am |
RNS |
Holding(s) in Company |
| 13th Jan 2023 7:16 am |
EQS |
Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability |
| 12th Jan 2023 2:40 pm |
RNS |
Holding(s) in Company |
| 12th Jan 2023 2:15 pm |
RNS |
Holding(s) in Company |
| 9th Jan 2023 5:10 pm |
RNS |
Partial AOP Loan Conversion |
| 9th Jan 2023 3:56 pm |
RNS |
Holding(s) in Company |
| 9th Jan 2023 3:25 pm |
RNS |
Holding(s) in Company |
| 5th Jan 2023 3:45 pm |
RNS |
Result of General Meeting & Open Offer |
| 28th Dec 2022 7:00 am |
RNS |
Total Voting Rights Update |
| 28th Dec 2022 7:00 am |
RNS |
PDMR Transaction Notification |
| 16th Dec 2022 7:00 am |
RNS |
Publication of Circular &Notice of General Meeting |
| 13th Dec 2022 3:45 pm |
RNS |
Successful completion of US$18.5m Equity Fundraise |
| 13th Dec 2022 7:02 am |
RNS |
Investor presentation |
| 13th Dec 2022 7:01 am |
RNS |
Placing & Subscription to raise approx. US$18m |
| 13th Dec 2022 7:00 am |
RNS |
Collaborative Sales Agreement signed with Viatris |
| 31st Oct 2022 7:00 am |
RNS |
Republic of Korea update |
| 27th Oct 2022 7:00 am |
RNS |
Shelf-life for Accrufer® extended to 48 months |
| 24th Oct 2022 7:00 am |
RNS |
Data presented at ACG Annual Scientific Meeting |
| 30th Sep 2022 7:00 am |
RNS |
Block Listing 6 Monthly Return |
| 15th Sep 2022 1:52 pm |
EQS |
Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building |
| 14th Sep 2022 2:17 pm |
RNS |
Holding(s) in Company |
| 8th Sep 2022 7:00 am |
RNS |
Half-year Report |
| 1st Sep 2022 2:20 pm |
RNS |
Holding(s) in Company |
| 1st Sep 2022 7:00 am |
RNS |
Launch of new corporate brand and website |
| 31st Aug 2022 2:00 pm |
RNS |
Total Voting Rights Update |
| 31st Aug 2022 11:00 am |
RNS |
Notice of Interim Results |
| 30th Aug 2022 9:30 am |
RNS |
Holding(s) in Company |
| 12th Aug 2022 11:45 am |
EQS |
Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous |
| 9th Aug 2022 4:45 pm |
RNS |
Grant of share options |
| 1st Aug 2022 7:00 am |
RNS |
Completion of Loan Agreement & Partial Conversion |
| 27th Jul 2022 4:20 pm |
RNS |
Results of 2022 General Meeting |
| 27th Jul 2022 4:15 pm |
RNS |
Results of 2022 Annual General Meeting |
| 26th Jul 2022 7:15 am |
EQS |
Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US |
| 14th Jul 2022 7:00 am |
RNS |
New Drug Submission accepted by Health Canada |
| 8th Jul 2022 7:00 am |
RNS |
Notice of General Meeting |
| 30th Jun 2022 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 30th Jun 2022 4:36 pm |
RNS |
Price Monitoring Extension |
| 30th Jun 2022 2:06 pm |
RNS |
Second Price Monitoring Extn |
